LoadingLoadingLoadingNet selling: insiders sold $66.1M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (2)
AQR
$231.3M
added
Bank of America
$124.5M
added
Sells/Trims (1)
D.E. Shaw
$97.1M
trimmed
No tracked top-trader positions in RVMD as of Oct 24, 09:20 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 5, 2026
Period ending
Jun 30, 2026
Earnings per share
-$1.93 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 24, 2026
EPS expected
-$3.26 to -$2.07
Revenue expected
21 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 5, 2026 | -$2.34 / -$1.93Alpha Vantage | -21.24% miss | $0.00 No estimate | Unavailable |
| Mar 31, 2026 | May 6, 2026 | -$2.29 / -$1.84Alpha Vantage | -24.46% miss | $0.00 No estimate | Unavailable |
| Dec 31, 2025 | Feb 25, 2026 | -$1.86 / -$1.58Alpha Vantage | -17.72% miss | $0.00 No estimate | Unavailable |
| Sep 30, 2025 | Nov 5, 2025 | -$1.61 / -$1.39Alpha Vantage | -15.83% miss | $0.00 No estimate | Unavailable |
| Jun 30, 2025 | Aug 6, 2025 | -$1.31 / -$1.12Alpha Vantage | -16.96% miss | $0.00 No estimate | Unavailable |
| Mar 31, 2025 | May 7, 2025 | -$1.13 / -$1.06Alpha Vantage | -6.60% miss | $0.00 No estimate | Unavailable |
| Dec 31, 2024 | Feb 26, 2025 | -$1.12 / -$0.96Alpha Vantage | -16.12% miss | $261.6M No estimate | Unavailable |
| Sep 30, 2024 | Nov 6, 2024 | -$0.94 / -$0.88Alpha Vantage | -6.82% miss | $0.00 No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $0 | $0 | $0 | $0 |
| Cost of what it sold | — | $4.7M | $4.5M | — |
| Gross profit | — | -$4.7M | -$4.5M | — |
| What it spent | ||||
| Research and development | $262.5M | $292.6M | $344.0M | $394.9M |
| Sales and admin | $52.8M | $64.3M | $101.3M | $110.2M |
| Other operating costs | — | — | -$4.5M | — |
| Total operating expenses | $315.3M | $356.9M | $440.7M | $505.1M |
| What was left | ||||
| Operating profit | -$315.3M | -$361.6M | -$445.2M | -$505.1M |
| Interest on debt | $11.4M | $11.9M | $12.2M | $23.8M |
| Profit before tax | -$305.2M | -$364.9M | -$453.8M | -$644.4M |
| Net profit | -$305.2M | -$364.9M | -$453.8M | -$644.4M |
| EBITDA | -$289.4M | -$348.3M | -$437.1M | -$616.1M |
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Revolution Medicines, Inc. - Common Stock (Nasdaq:RVMD) Stock Quote
BullishOct 21Revolution Medicines Inc Stock (RVMD) Moved Up by 7.41% on Oct 20: Facts Behind the Movement
BullishOct 20Revolution Medicines Begins Phase 3 RASolve 308 Trial of Zoldonrasib in RAS G12D Non-squamous NSCLC
BullishOct 20Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment
BullishOct 20Revolution Medicines begins phase 3 trial for lung cancer drug
BullishOct 20Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung
BullishOct 20Some people with advanced lung cancer have no approved targeted treatment. A drug combination is now being tested.
BullishOct 20Price to sales forward of Revolution Medicines, Inc. – BOATS:RVMDW
NeutralOct 19
